These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 10848719)

  • 1. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
    Kerbusch T; Huitema AD; Ouwerkerk J; Keizer HJ; Mathôt RA; Schellens JH; Beijnen JH
    Br J Clin Pharmacol; 2000 Jun; 49(6):555-61. PubMed ID: 10848719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
    Kerbusch T; Mathĵt RA; Keizer HJ; Ouwerkerk J; Rodenhuis S; Schellens JH; Beijnen JH
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):467-77. PubMed ID: 11699611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic modelling of ifosfamide administered by continuous infusion on 5 days at the dose of 6 g/m2.
    Passe P; Delepine N; Arnaud P; Urien S; Delepine G; Traoré F; Desbois JC; Brion F
    Anticancer Res; 1999; 19(1B):837-42. PubMed ID: 10216502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
    Kerbusch T; de Kraker J; Mathĵt RA; Beijnen JH
    Clin Pharmacokinet; 2001; 40(8):615-25. PubMed ID: 11523727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
    Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C
    J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
    Lokiec F; Santoni J; Weill S; Tubiana-Hulin M
    Anticancer Drugs; 1996 Nov; 7(8):893-6. PubMed ID: 8991196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
    Kerbusch T; vanPutten JW; Groen HJ; Huitema AD; Mathĵt RA; Beijnen JH
    Cancer Chemother Pharmacol; 2001 Jul; 48(1):53-61. PubMed ID: 11488525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
    Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
    Chugh R; Wagner T; Griffith KA; Taylor JM; Thomas DG; Worden FP; Leu KM; Zalupski MM; Baker LH
    Cancer; 2007 Jun; 109(11):2315-22. PubMed ID: 17464949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide according to continuous or short infusion schedules: an n = 1 randomized study.
    Brain EG; Rezai K; Lokiec F; Gutierrez M; Urien S
    Br J Clin Pharmacol; 2008 Apr; 65(4):607-10. PubMed ID: 18294323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
    Boddy AV; English M; Pearson AD; Idle JR; Skinner R
    Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.
    Lewis LD
    Br J Clin Pharmacol; 1996 Aug; 42(2):179-86. PubMed ID: 8864315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of AUC-directed carboplatin with infusional doxorubicin and ifosfamide plus G-CSF in patients with advanced gynecologic malignancies.
    Lopez AM; Ketchum M; Nichols H; Xu MJ; Peng YM; Dorr R; Alberts DS
    Cancer Chemother Pharmacol; 2000; 46(5):411-5. PubMed ID: 11127946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
    Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
    Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
    Mace JR; Keohan ML; Bernardy H; Junge K; Niebch G; Romeis P; Thoma A; Wagner T; Mueller U; Demetri G; Baker LH
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5829-34. PubMed ID: 14676103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion.
    Boddy AV; Cole M; Pearson AD; Idle JR
    Cancer Chemother Pharmacol; 1995; 36(1):53-60. PubMed ID: 7720176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
    Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines.
    Chang TK; Yu L; Maurel P; Waxman DJ
    Cancer Res; 1997 May; 57(10):1946-54. PubMed ID: 9157990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.